
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$41.10
+US$1.85 · +4.71%
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
前收盘价
US$41.10
+US$1.85 · +4.71%
盘中时间采用ET。市场数据可能有所延迟。
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
日内区间
当前US$41.10
52周区间
当前US$41.10
盘中时间采用ET。市场数据可能有所延迟。
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
日内区间
当前US$41.10
52周区间
当前US$41.10
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 172.57亿 USD | 165.44亿 USD | 158.45亿 USD | 149.25亿 USD | 158.78亿 USD |
| 销货成本 | 83.2亿 USD | 84.81亿 USD | 82亿 USD | 79.52亿 USD | 82.84亿 USD |
| 毛利 | 89.38亿 USD | 80.63亿 USD | 76.45亿 USD | 69.73亿 USD | 75.94亿 USD |
| 研究与开发 | 10.13亿 USD | 10.55亿 USD | 9.53亿 USD | 8.38亿 USD | 10.94亿 USD |
| 销售、一般及管理费用 | 39.73亿 USD | 37.02亿 USD | 34.98亿 USD | 34.45亿 USD | 35.28亿 USD |
| 营业费用 | 67.8亿 USD | 83.66亿 USD | 72.12亿 USD | 91.7亿 USD | 58.78亿 USD |
| 利息收入 | — | — | 6800万 USD | — | — |
| 利息支出 | 9.16亿 USD | 9.41亿 USD | 10.29亿 USD | 9.3亿 USD | 8.91亿 USD |
| 折旧和摊销 | 10.02亿 USD | 10.59亿 USD | 11.53亿 USD | 13.08亿 USD | 13.3亿 USD |
| 营业利润 | 21.57亿 USD | −3.03亿 USD | 4.33亿 USD | −21.97亿 USD | 17.16亿 USD |
| 净利润 | 14.1亿 USD | −16.39亿 USD | −5.59亿 USD | −24.46亿 USD | 4.17亿 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Core MSCI EAFE ETFIEFA3.48亿0.19%1894.71亿 USD0.07%US$96.52+0.68%
iShares MSCI EAFE ETFEFA1.64亿0.22%765.34亿 USD0.32%US$103.4+0.68%
Schwab International Equity ETFSCHF1.04亿0.15%674.08亿 USD0.03%US$27.27+0.66%
iShares MSCI Israel ETFEIS9841.45万11.49%8.6亿 USD0.59%US$118.28+0.54%
First Trust WCM International Equity ETFWCMI7978.94万3.81%20.87亿 USD0.85%US$19.05+1.06%
iShares MSCI EAFE Growth ETFEFG6494.18万0.44%150.87亿 USD0.34%US$120.3+1.05%
iShares Core MSCI Total International Stock ETFIXUS6320.6万0.11%586.25亿 USD0.07%US$94.99+0.90%
iShares Core MSCI International Developed Markets ETFIDEV5496.97万0.17%331.28亿 USD0.04%US$89.21+0.73%
iShares Core MSCI EAFE ETFIEFA
iShares MSCI EAFE ETFEFA
Schwab International Equity ETFSCHF
iShares MSCI Israel ETFEIS
First Trust WCM International Equity ETFWCMI
iShares MSCI EAFE Growth ETFEFG
iShares Core MSCI Total International Stock ETFIXUS
iShares Core MSCI International Developed Markets ETFIDEVAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。